This study is currently not recruiting participants.

A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL

Study on Treatment Adherence in Children with Acute Lymphoblastic Leukemia

Not Recruiting
1 years - 21 years
All
Phase N/A

Brief description of study.

This randomized phase III trial studies compliance to a mercaptopurine treatment intervention compared to standard of care in younger patients with acute lymphoblastic leukemia in remission.

Detailed description of study

The purpose of this study is to determine the impact of interventions proposed in intervention program (IP) vs. education alone (EDU) on adherence to oral 6MP (mercaptopurine) in children with acute lymphoblastic leukemia (ALL).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pediatric acute lymphoblastic leukemia
  • Age: 1 years - 21 years
  • Gender: All

This study investigates the treatment adherence in children with acute lymphoblastic leukemia (ALL), a type of blood cancer that affects white blood cells. The purpose of this study is to compare the impact of an intervention program with education alone on how well young patients stick to their prescribed treatment plan.

Participants in the study will be randomly assigned to one of two study arms. One arm will receive an intervention program designed to improve adherence to their medication schedule. The other arm will receive educational support to help them understand the importance of taking their medication as prescribed.

  • Who can participate: Participants are children diagnosed with acute lymphoblastic leukemia who are currently in remission. The study is focused on younger patients, specifically those aged 2 to 18, who are prescribed oral mercaptopurine as part of their treatment plan.
  • Study details: Participants will be randomly assigned to receive either an intervention program or educational support. The intervention program aims to improve medication adherence, while the educational support provides information on the importance of following the treatment plan. A placebo is not used in this study.
Updated on 19 Feb 2024. Study ID: 1206008928 (PHO-COG-FALLO

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team